{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:08:13Z","timestamp":1788836893944,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007420","name":"L\u00e6geforeningen","doi-asserted-by":"publisher","award":["2019-3780\/41"],"award-info":[{"award-number":["2019-3780\/41"]}],"id":[{"id":"10.13039\/501100007420","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF170C0029064"],"award-info":[{"award-number":["NNF170C0029064"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010078","name":"Region Midtjylland","doi-asserted-by":"publisher","award":["A3192"],"award-info":[{"award-number":["A3192"]}],"id":[{"id":"10.13039\/501100010078","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jdiacomp.2026.109397","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:28:14Z","timestamp":1787984894000},"page":"109397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8275-1278","authenticated-orcid":false,"given":"S\u00f8ren","family":"Gullaksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-435X","authenticated-orcid":false,"given":"Liv","family":"Vernstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen Skovgaard","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0213-5550","authenticated-orcid":false,"given":"Kristian L\u00f8kke","family":"Funck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-2715","authenticated-orcid":false,"given":"Per L\u00f8gstrup","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1782-1596","authenticated-orcid":false,"given":"Esben","family":"Laugesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2026.109397_bb0005","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular Disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11154-010-9134-4","article-title":"Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications","volume":"11","author":"Tabit","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0015","first-page":"S181","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","author":"Committee ADAPP","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0020","first-page":"S207","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"Committee ADAPP","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis-an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0030","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehq010","article-title":"Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events","volume":"31","author":"Rubinshtein","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0035","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1161\/01.CIR.96.12.4219","article-title":"Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid Atherosclerosis and incident coronary heart Disease cases","volume":"96","author":"Hwang","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0040","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1161\/hc3701.095949","article-title":"Circulating cell adhesion molecules and death in patients with coronary artery Disease","volume":"104","author":"Blankenberg","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.atherosclerosis.2019.06.908","article-title":"Association between circulating cell adhesion molecules and risk of type 2 diabetes: a meta-analysis","volume":"287","author":"Qiu","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0050","article-title":"Endothelial cell adhesion molecules- (un)attainable targets for nanomedicines","volume":"4","author":"Milo\u0161evi\u0107","year":"2022","journal-title":"Rev Front Med Technol"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0055","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","article-title":"Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial","volume":"66","author":"Gullaksen","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0060","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/dom.15464","article-title":"Separate and combined effects of empagliflozin and semaglutide on vascular function: a 32-week randomized trial","volume":"26","author":"Vernstr\u00f8m","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0065","doi-asserted-by":"crossref","DOI":"10.3791\/2167","article-title":"Assessing endothelial vasodilator function with the Endo-PAT 2000","author":"Axtell","year":"2010","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0070","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.118.11554","article-title":"Physiological Diagnostic Criteria for Vascular Failure","volume":"72","author":"Tanaka","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/cei.13315","article-title":"Circulating lectin pathway proteins do not predict short-term cardiac outcomes after myocardial infarction","volume":"198","author":"Holt","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0080","series-title":"Applied Longitudinal Analysis","first-page":"695","author":"Fitzmaurice","year":"2011"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.120.012174","article-title":"Effect of liraglutide on arterial inflammation assessed as 18FDG uptake in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Ripa","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s13300-018-0560-8","article-title":"Effect of Dulaglutide versus Liraglutide on glucose variability, oxidative stress, and endothelial function in type 2 diabetes: a prospective study","volume":"10","author":"Nagaike","year":"2019","journal-title":"Diab Ther"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01183-5","article-title":"Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial","volume":"20","author":"Tuttolomondo","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0100","doi-asserted-by":"crossref","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","article-title":"Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease","volume":"287","author":"Nystr\u00f6m","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0105","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.2337\/dc19-1177","article-title":"Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: results from the multicenter, randomized, placebo-controlled, double-blind EMBLEM trial","volume":"42","author":"Tanaka","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0110","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/jdi.13289","volume":"11","author":"Tanaka","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101447","article-title":"Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: a randomized clinical trial (PROCEED)","volume":"49","author":"Tanaka","year":"2023","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.826604","article-title":"Effects of SGLT-2 inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes: a systematic review and Meta-analysis of randomized controlled trials","volume":"13","author":"Wei","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0125","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002270","article-title":"Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis","volume":"4","author":"Matsuzawa","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0130","article-title":"Effect of GLP-1RA treatment on adhesion molecules and monocyte chemoattractant protein-1 in diabetic patients with atherosclerosis","volume":"14","author":"Hachu\u0142a","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0135","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1464-5491.2012.03589.x","article-title":"Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function","volume":"29","author":"Forst","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0140","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamacardio.2025.1592","article-title":"Cellular adhesion molecules and adverse outcomes in chronic heart failure: findings from the DAPA-HF randomized clinical trial","volume":"10","author":"McDowell","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0145","article-title":"Does empagliflozin modulate leukocyte\u2013endothelium interactions, oxidative stress, and inflammation in type 2 diabetes?","volume":"10","author":"Canet","year":"2021","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137274","article-title":"Endothelial protection by sodium-glucose cotransporter 2 inhibitors: a literature review of in vitro and in vivo studies","volume":"25","author":"Mylonas","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0155","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0160","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2026.109397_bb0165","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ekir.2021.05.022","article-title":"Markers of kidney injury, inflammation, and fibrosis associated with Ertugliflozin in patients with CKD and diabetes","volume":"6","author":"Liu","year":"2021","journal-title":"Kidney Int Rep"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272600142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272600142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:29:30Z","timestamp":1788834570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105687272600142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S105687272600142X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109397","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"109397"}}